Schering-Plough Corp. and Merck & Co. narrowed the agency review for their co-marketed cholesterol-lowering drug to two shops. DDB
Worldwide and Grey Worldwide, both New York, are believed to be the finalists, according to executives close to the situation. Y&R Advertising, New York, was cut from the process. The product, known by the generic name ezetimibe, is expected to hit the market in two years.
Copyright December 2000, Crain Communications Inc.